American Heart Association

FDA rules may be adding law and order to e-cigarettes

By AMERICAN HEART ASSOCIATION NEWS

Until recently, the sale of e-cigarettes was like the Wild West, with almost no regulations for what ingredients they contained or how old you had to be to buy them.

But new rules from the U.S. Food and Drug Administration are adding some semblance of law […]

La FDA propone metas voluntarias para la reducción de sodio para los fabricantes alimenticios

Por AMERICAN HEART ASSOCIATION NEWS

Read in English

El gobierno federal ha propuesto metas voluntarias nuevas para que restaurantes y fabricantes de alimentos rebajen gradualmente la cantidad de sal en sus productos, una de varias medidas significativas recientes que buscan reducir la cantidad de sodio en los alimentos de Estados Unidos.

El consumo alto […]

FDA proposes voluntary targets for food producers to lower sodium

By AMERICAN HEART ASSOCIATION NEWS

Lea en español

The federal government has proposed voluntary new targets for restaurants and food manufacturers to gradually lower the amount of salt in their products, the latest in a series of significant moves aiming to reduce sodium in the U.S. food supply.

High sodium intake has […]

FDA issues regulations for e-cigarettes, other tobacco products

By AMERICAN HEART ASSOCIATION NEWS

The Food and Drug Administration on Thursday released new rules that extend its regulatory authority to electronic cigarettes, cigars, cigarillos, pipe tobacco and hookah tobacco.

More than two years in the making, the new requirements prohibit the sale of these newly regulated tobacco products to Americans […]

FDA warns of severe joint pain with certain diabetes drugs

By AMERICAN HEART ASSOCIATION NEWS

A class of Type 2 diabetes drugs called DPP-4 inhibitors may cause severe and disabling joint pain, the U.S. Food and Drug Administration said Friday.

The FDA warned that sitagliptin, saxagliptin, linagliptin and alogliptin were linked to 33 cases of severe joint pain from October 2006, […]

August 28th, 2015|Categories: Blog|Tags: , , , |1 Comment

FDA issues warnings to ‘natural’ tobacco makers

By AMERICAN HEART ASSOCIATION NEWS

The U.S. Food and Drug Administration issued warning letters Thursday to tobacco makers ITG Brands LLC, Santa Fe Natural Tobacco Company Inc. and Sherman’s 1400 Broadway N.Y.C. Ltd. for labels claiming their cigarettes are “additive-free” or “natural.”

The manufacturers must receive FDA approval to legally sell […]

August 27th, 2015|Categories: Blog, Uncategorized|Tags: , , |0 Comments

The too-sweet truth: FDA proposes daily value measures on added sugars

By AMERICAN HEART ASSOCIATION NEWS

The U.S. Food and Drug Administration proposed Friday that a “percent daily value” for added sugars be part of nutrition labels on packaged foods providing consumers more information about how added sugar fits into their daily diets.

The information would be similar to what Americans have […]

July 24th, 2015|Categories: Blog, Uncategorized|Tags: , |2 Comments

FDA tells food makers to phase out trans fats

By AMERICAN HEART ASSOCIATION NEWS

The Food and Drug Administration on Tuesday issued a ruling that effectively bans trans fats from the nation’s food supply, transforming processed foods in America.

The FDA’s final ruling revokes the “generally recognized as safe” classification for partially hydrogenated oils, the main source of trans fats in […]

June 16th, 2015|Categories: Blog, Uncategorized|Tags: , |1 Comment

Clinical trial results could be made public

A proposal to open the results of clinical trials to the public is an encouraging move toward transparency, but the American Heart Association President cautions that how that information is shared and how patients and clinicians are protected from mistakes should be a key part of any change.

The Department […]

No decision yet by FDA about testosterone limits suggested by panel

Limitations on how testosterone is used and marketed remain under consideration at the Food and Drug Administration following a recent advisory panel recommendation.

The Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee made two recommendations to the agency at a joint meeting […]